9. SEGMENT REPORTING (Tables)

6 Months Ended

Oct. 31, 2016

Segment Reporting [Abstract]

Segment information

	Three Months Ended October 31,						Six Months Ended October 31,
	2016			2015			2016			2015
Contract manufacturing services revenue	$	23,370,000		$	9,523,000		$	28,979,000		$	18,902,000
Cost of contract manufacturing services		15,441,000			4,741,000			18,503,000			9,349,000
Gross profit		7,929,000			4,782,000			10,476,000			9,553,000
Revenue from products in research and development		–			–			–			292,000
Research and development expense		(7,022,000	)		(14,190,000	)		(15,591,000	)		(28,108,000	)
Selling, general and administrative expense		(4,984,000	)		(4,416,000	)		(10,044,000	)		(9,315,000	)
Interest and other income		21,000			626,000			46,000			657,000
Net loss	$	(4,056,000	)	$	(13,198,000	)	$	(15,113,000	)	$	(26,921,000	)

	October 31, 2016		April 30, 2016
Long-lived Assets, net:
Contract manufacturing services	$	22,594,000	$	22,783,000
Products in research and development		1,363,000		1,519,000
Total	$	23,957,000	$	24,302,000

Customer Revenue

	Three Months Ended October 31,				Six Months Ended October 31,
Customer	2016		2015		2016		2015
Halozyme Therapeutics, Inc.		77%		56%		74%		70%
Customer A		10		41		14		28
Customer B		12		–		10		–
Other customers		1		3		2		2
Total		100%		100%		100%		100%